Purpose: We have investigated the use of human urine as a non-invasive medium to screen for molecular biomarkers of carcinomas of the upper gastrointestinal (uGI) tract using SELDI-TOF-MS. Experimental design: A total of 120 urine specimens from 60 control and 60 uGI cancer patients were analysed to establish a potential biomarker fingerprint for the weak cation exchanger CM10 chip surface, which was validated by blind testing using a further 59 samples from 33 control and 26 uGI cancer patients. Results: Using Biomarker Pattern software, we established a model with a sensitivity of 98% and specificity of 95% for the learning sample set, and a sensitivity of 96% and specificity of 72% for the validation data set. Model variable importance included six peptides with m/z of 10â€‰230, 10â€‰436, 10â€‰574, 10â€‰311, 10â€‰467, and 1â€‰0118 of which the 10â€‰230 molecular species was the main decider (sensitivity 86% and specificity 80. Initial protein database searching identified 10â€‰230 as S100-A6, 10â€‰436 as S100-P, 10â€‰467 as S100-A9, and 10â€‰574 as S100-A12 of which S100-A6 and S100-A9 were confirmed by Western blotting. Conclusions and clinical relevance: We have demonstrated that SELDI-TOF-MS as a screening tool is a rapid and valid methodology in the search for urinary cancer biomarkers, and is potentially useful in defining and consolidating biomarker patterns for uGI cancer screening.
|Number of pages||11|
|Journal||Proteomics Clinical Applications|
|Publication status||Published - 1 Jun 2011|